The Juvenile Diabetes Research Foundation (JDRF) announced that a series of five clinical trials “may hold groundbreaking clues that would alter the course of type 1 diabetes.”
One such trial focuses on the effectiveness of oral insulin capsules in delaying the development of type 1. Another trial focuses on the immune and metabolic profiles of people at risk for developing the disease.
These clinical trials, in addition to three more protocols to be launched in early 2006, are part of TrialNet, an umbrella organization for clinical trials aimed to prevent type 1 diabetes, circumvent development of the disease and slow disease progression in newly diagnosed people.
According to the JDRF, TrialNet is part of a special funding initiative for type 1 diabetes research created by Congress in 1998 that allocates $1.14 billion over 11 years to the National Institutes of Health (NIH).
TrialNet’s other main studies will include:
- a Natural History Study that focuses on the profiles of people at risk for developing type 1 diabetes
- an anti-CD20 trial that will administer rituximab, an anti-CD20 monoclonal antibody that targets and destroys B-cells
- a Nutritional Intervention Prevention Trial that would enroll pregnant women and infants at high risk for developing type 1 diabetes to help determine whether high doses of omega-3 fatty acids prolong or delay disease onset by preventing an inflammatory response in the immune system.
The studies will be carried out in 14 clinical centers throughout the United States and Canada with additional sites in the United Kingdom, Italy, Germany, Finland and Australia.
* * *
Source: The Juvenile Diabetes Research Foundation, December 7, 2005